<DOC>
	<DOCNO>NCT01762891</DOCNO>
	<brief_summary>Coumadin drug-drug interaction ( DDI ) frequent . Patients permanent use coumadin advise avoid traditional nonsteroidal antiinflammatory drug avoid risk bleeding . New selctive cyclooxygesase 2 inhibitor arise potential option treat pain inflamation patient interaction coumadin suppose low . The CI ( R ) CA study make evaluate prospective fashion occurrence DDI new cyclooxygenase antiinflammatory drug coumadin compare acetaminophen placebo .</brief_summary>
	<brief_title>CI ( R ) CA : Coumadin Interaction With Rofecoxib , Celecoxib Acetaminophen</brief_title>
	<detailed_description>The CI ( R ) CA study include patient diagnose antiphospholipid syndrome permanent use coumadin . Eligible patient invite use prospective cross-over mode two week celecoxib , rofecoxib , acetaminophen placebo two week wash drug . Their international normalize ratio ( INR ) measure use study drug . The interaction coumadin evaluate accord increase decrease INR medication .</detailed_description>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>PAPS contious stable dose coumadin 18 year old old Younger 65 yo Signed informed consent . Renal failure Heart failure Symptomatic gastritis peptic ulcer Elevated liver enzymes ( &gt; 3 fold ) Platelet count &lt; 100,000 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Coumadin</keyword>
	<keyword>celecoxib</keyword>
	<keyword>rofecoxib</keyword>
	<keyword>acetaminophen</keyword>
	<keyword>antiphospholipid syndrome INR</keyword>
</DOC>